{"output": [["Allergan Plc", "ORG", "Cut", "over 1,000 jobs", "GPE"], ["Allergan Plc", "ORG", "Eliminate", "an additional 400 currently open positions", "GPE"], ["Allergan Plc", "ORG", "Works", "cut costs", "CONCEPT"], ["Allergan Plc", "ORG", "Works", "face new competition", "CONCEPT"], ["Allergan Plc", "ORG", "Has", "second most important drug", "PRODUCT"], ["Restasis", "PRODUCT", "Generates", "$1.5 billion in sales", "ECON_INDICATOR"], ["Allergan Plc", "ORG", "Strikes", "a controversial deal", "CONCEPT"], ["Allergan Plc", "ORG", "Shield", "review of the patents", "CONCEPT"], ["US Regulators", "ORG/REG", "Regulate", "patents", "CONCEPT"], ["Allergan Plc", "ORG", "Draws", "ire of lawmakers", "PERSON"], ["Rival drug companies", "ORG", "Draw", "ire of", "ORG"], ["Allergan Plc", "ORG", "Invalidates", "Restasis patents", "CONCEPT"], ["Texas federal judge", "ORG/GOV", "Invalidates", "Restasis patents", "CONCEPT"], ["Allergan Plc", "ORG", "Appeals", "the ruling", "CONCEPT"], ["Allergan Plc", "ORG", "Employs", "18,000 people", "GPE"], ["Allergan Plc", "ORG", "Works", "expand its base business", "CONCEPT"], ["Allergan Plc", "ORG", "Works", "reduce costs", "CONCEPT"], ["Allergan Plc", "ORG", "Return", "to earnings growth", "CONCEPT"], ["Shares of Allergan", "FIN_INSTRUMENT", "Rise", "$1.45", "ECON_INDICATOR"], ["Shares of Allergan", "FIN_INSTRUMENT", "Increase", "0.9 percent", "ECON_INDICATOR"], ["Shares of Allergan", "FIN_INSTRUMENT", "Trade", "at $171.77", "ECON_INDICATOR"]], "published": "2018-01-04T01:18:00.000+02:00"}